+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Critical Care Antiarrhythmic Drugs Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797896
The global market value in 2022 was USD 1005.2 million, driven rising demand for advanced healthcare facilities across the globe. The critical care antiarrhythmic drugs market size is anticipated to grow at a CAGR of 5.6% during the forecast period of 2023-2031 to achieve a value of USD 1644.2 billion by 2031.

Critical Care Antiarrhythmic Drugs: Introduction

Critical care antiarrhythmic drugs are medications that are used to treat irregular heartbeats, also known as arrhythmias, which can be life-threatening in some cases. These drugs are used in critical care settings such as intensive care units (ICUs) and emergency departments to manage and stabilize patients with severe arrhythmias.

Some common antiarrhythmic drugs used in critical care include amiodarone, lidocaine, and procainamide. These drugs work by slowing down or controlling the electrical impulses in the heart, thereby regulating the heartbeat.

The global critical care antiarrhythmic drugs market is expected to grow due to the increasing prevalence of cardiovascular diseases, rising demand for advanced healthcare facilities, and the growing geriatric population. Additionally, the development of novel antiarrhythmic drugs and the emergence of new treatment options is expected to further drive market growth.

However, the high cost of these drugs and the potential side effects associated with their use may hinder market growth to some extent. Overall, the critical care antiarrhythmic drugs market is expected to experience significant growth in the coming years.

Key Trends in the Critical Care Antiarrhythmic Drugs Market

Some key trends in the critical care antiarrhythmic drugs market include:

  • Increasing prevalence of cardiac arrhythmias: With the growing aging population and increasing incidence of cardiovascular diseases, the prevalence of cardiac arrhythmias is on the rise, which is driving the demand for antiarrhythmic drugs
  • Technological advancements: Advancements in drug delivery technologies, such as sustained-release formulations, are enhancing the efficacy and safety of antiarrhythmic drugs, thereby boosting their adoption
  • Increasing demand for personalized medicine: There is a growing trend towards personalized medicine, with healthcare providers opting for tailored treatment plans for individual patients. This trend is expected to drive the development of antiarrhythmic drugs that are more effective and have fewer side effects
  • Emergence of novel therapies: The development of novel therapies, such as gene therapy and stem cell therapy, for the treatment of cardiac arrhythmias is expected to revolutionize the market, providing more options for patients and driving growth in the market
  • Rising healthcare expenditure: With the increasing focus on healthcare and growing healthcare expenditure, the demand for critical care antiarrhythmic drugs is expected to rise in the coming years

Critical Care Antiarrhythmic Drugs Market Segmentations

Market Breakup by Drug Class

  • Beta Blockers
  • Calcium Chain Blockers
  • Sodium Channel Blockers
  • Potassium Channel Blockers
  • Others

Market Breakup by Diseases Type

  • Supraventricular Arrhythmias
  • Ventricular Arrhythmias
  • Others

Market Breakup by Route of Administration


  • Tablets
  • Capsules


  • Intravascular
  • Intramuscular
  • Others

Market Breakup by Treatment Channel

  • Public
  • Private

Market Breakup by End User

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Critical Care Antiarrhythmic Drugs Market Scenario

Critical care antiarrhythmic drugs are medications used to treat and prevent abnormal heart rhythms, known as arrhythmias, in critically ill patients. These drugs are typically administered in emergency or critical care settings and can be used to treat a range of arrhythmias, from mild to life-threatening.

The market for critical care antiarrhythmic drugs is driven by the growing incidence of arrhythmias in critically ill patients, coupled with the increasing demand for effective treatment options. As the global population ages and the prevalence of chronic conditions such as cardiovascular disease and diabetes continues to rise, the need for critical care antiarrhythmic drugs is expected to grow.

In addition to traditional drugs such as beta-blockers and calcium channel blockers, newer classes of critical care antiarrhythmic drugs, such as sodium channel blockers and potassium channel blockers, are emerging as promising treatment options. These drugs offer greater efficacy and fewer side effects compared to older drugs, further fuelling market growth.

Other factors contributing to the growth of the critical care antiarrhythmic drugs market include increasing investments in research and development, rising healthcare spending, and improving healthcare infrastructure in developing economies.

Critical Care Antiarrhythmic Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the critical care antiarrhythmic drugs market are as follows:
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd
  • Novartis AG
  • Mylan N.V
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Lupin
  • GSK Plc
  • Glenmark Pharmaceuticals Inc
  • Amneal Pharmaceuticals

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Arrhythmias Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Arrhythmias Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Arrhythmia Epidemiology (2016-2031)
5.3 Europe Arrhythmia Epidemiology (2016-2031)
5.4 Asia-Pacific Arrhythmia Epidemiology (2016-2031)
5.5 Latin America Arrhythmia Epidemiology (2016-2031)
5.6 Middle East & Africa Arrhythmia Epidemiology (2016-2031)
6 Global Critical Care Antiarrhythmic Drugs Market Overview
6.1 Global Critical Care Antiarrhythmic Drugs Market Historical Value (2016-2022)
6.2 Global Critical Care Antiarrhythmic Drugs Market Forecast Value (2023-2031)
7 Global Critical Care Antiarrhythmic Drugs Market Landscape
7.1 Critical Care Antiarrhythmic Drugs: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Critical Care Antiarrhythmic Drugs: Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Disease Type
7.2.3 Analysis by Route of Administration
8 Critical Care Antiarrhythmic Drugs Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Critical Care Antiarrhythmic Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Critical Care Antiarrhythmic Drugs Market Segmentation
11.1 Global Critical Care Antiarrhythmic Drugs Market by Drug Class
11.1.1 Market Overview
11.1.2 Beta Blockers
11.1.3 Calcium Chain Blockers
11.1.4 Sodium Channel Blockers
11.1.5 Potassium Channel Blockers
11.1.6 Others
11.2 Global Critical Care Antiarrhythmic Drugs Market by Diseases Type
11.2.1 Market Overview
11.2.2 Supraventricular Arrhythmias
11.2.3 Ventricular Arrhythmias
11.2.4 Others
11.3 Global Critical Care Antiarrhythmic Drugs Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral Tablets Capsules
11.3.3 Parentals Intravascular Intramuscular
11.3.4 Others
11.4 Global Critical Care Antiarrhythmic Drugs Market by Treatment Channel
11.4.1 Market Overview
11.4.2 Public
11.4.3 Private
11.5 Global Critical Care Antiarrhythmic Drugs Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Homecare Settings
11.5.5 Others
11.6 Global Critical Care Antiarrhythmic Drugs Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.6.5 Others
11.7 Global Critical Care Antiarrhythmic Drugs Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.3 Europe
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Critical Care Antiarrhythmic Drugs Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Critical Care Antiarrhythmic Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Critical Care Antiarrhythmic Drugs Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Critical Care Antiarrhythmic Drugs Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Critical Care Antiarrhythmic Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 F. Hoffmann-La Roche Ltd.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Fresenius Kabi AG
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Bayer AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Sun Pharmaceutical Industries Ltd.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Novartis AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Mylan N.V.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Teva Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Pfizer Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Lupin
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 GSK Plc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Glenmark Pharmaceuticals Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Amneal Pharmaceuticals
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
24 Critical Care Antiarrhythmic Drugs Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Lupin
  • Gsk plc.
  • Glenmark Pharmaceuticals Inc.
  • Amneal Pharmaceuticals



Table Information